Food, Drugs, Healthcare, Life Sciences

The Trump Administration continues to advocate for "Most Favored Nation" (MFN) pharmaceutical drug pricing through executive action and voluntary agreements, but the Administration's high-profile deals may have limited impact. To date, 16 manufacturers have signed voluntary agreements to adopt MFN prices. These deals will only apply to state Medicaid programs and cash-paying consumers, which limits their impact.

On February 17, 2026, the U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP), chaired by Senator Bill Cassidy (R-LA), published a white paper outlining proposed...

As market conditions stabilize and capital begins to re-engage, contract development and manufacturing organizations (CDMOs) are emerging as central drivers of value creation across the MedTech ecosystem.